Related references
Note: Only part of the references are listed.Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?
Giuseppe Gritti et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi
Stefano Luminari et al.
HAEMATOLOGICA (2016)
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi
Stefano Luminari et al.
HAEMATOLOGICA (2016)
ROS: novel regulators of thrombopoiesis
Bing Zhang et al.
BLOOD (2016)
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
Gabor Kovacs et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn et al.
LANCET ONCOLOGY (2016)
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy
Fabian Zohren et al.
BLOOD (2015)
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
David M. Kurtz et al.
BLOOD (2015)
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
Sara Galimberti et al.
CLINICAL CANCER RESEARCH (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program
Marco Ladetto et al.
BLOOD (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
Mark Chao
Cancer Management and Research (2013)
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma
Chiara Lobetti-Bodoni et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucemies et Autres Maladies du Sang
Estelle Gimenez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
Howard Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Quantitative PCR Analysis for Bcl-2/IgH in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma
Lindsey Goff et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
Marco Ladetto et al.
BLOOD (2008)
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab:: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients
Carsten Hirt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
M Ladetto et al.
EXPERIMENTAL HEMATOLOGY (2003)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
JJM van Dongen et al.
LEUKEMIA (2003)
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
A Rambaldi et al.
BLOOD (2002)
Share Paper
